Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Finished Goods: 2019-2024

Historic Finished Goods for CorMedix (CRMD) over the last 3 years, with Dec 2024 value amounting to $3.0 million.

  • CorMedix's Finished Goods rose 1233.22% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year increase of 1233.22%. This contributed to the annual value of $3.0 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, CorMedix's Finished Goods is $3.0 million, which was up 831.51% from $317,733 recorded in FY2020.
  • CorMedix's 5-year Finished Goods high stood at $3.0 million for FY2024, and its period low was $317,733 during FY2020.
  • Its 1-year average for Finished Goods is $3.0 million, with a median of $3.0 million in 2024.
  • Data for CorMedix's Finished Goods shows a maximum YoY plummeted of 31.19% (in 2020) over the last 5 years.
  • Yearly analysis of 2 years shows CorMedix's Finished Goods stood at $317,733 in 2020, then followed by $3.0 million in 2024.